Skip to main content

Sen. Grassley says Mylan's $465 million Epi-Pen settlement 'shortchanges' taxpayers

The settlement came after an unusual lawsuit by Sanofi, a competitor to Mylan, which alleged anti-competitive tactics.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.